-

10:50:27 AM

SLS Stock News

SLS - SELLAS Life Sciences Group Inc

05/25/23 5:05 PM

Nasdaq : SLS

conferencesclinical trial

SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress

RHEA-AI

positive

05/16/23 8:30 AM

Nasdaq : SLS

conferences

SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of

RHEA-AI

neutral

05/11/23 4:12 PM

Nasdaq : SLS

earnings

SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results

Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient with Acute Myeloid Leukemia > 6 months Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute

RHEA-AI

neutral

05/04/23 8:30 AM

Nasdaq : SLS

clinical trial

SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

- 72 Acute Myeloid Leukemia and Lymphoma High-Risk Advanced Patients Enrolled: 94% Alive at Last Assessment Indicating Favorable Survival Benefit - - Long-Term Complete Remission and Significant Bone Marrow Blast Reductions in Acute Myeloid Leukemia: Durable Complete Remission with No Minimal

RHEA-AI

neutral

04/26/23 4:01 PM

Nasdaq : SLS

SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an

RHEA-AI

neutral

04/20/23 8:30 AM

Nasdaq : SLS

SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia

– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once weekly dosing – – GFH009 demonstrated a favorable tolerability profile with no dose limiting toxicities – – SELLAS plans to commence Phase 2a trial with GFH009 in combination with

RHEA-AI

positive

04/18/23 8:30 AM

Nasdaq : SLS

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development

RHEA-AI

neutral

03/16/23 4:11 PM

Nasdaq : SLS

earnings

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and Combination Treatment $20 Million of Gross Proceeds from Capital Raise in February 2023 Adds to

RHEA-AI

neutral

03/07/23 8:30 AM

Nasdaq : SLS

clinical trial

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal

Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting Immune Response Translated into Clear Clinical Benefit with 70% One-Year Progression-Free Survival Demonstrated in GPS-Treated

RHEA-AI

neutral

02/24/23 8:30 AM

Nasdaq : SLS

offering

SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

SLS Data

IndustryPharmaceutical Preparation Manufacturing
Websitesellaslifesciences.com
Security nameSELLAS Life Sciences Group Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees11
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2140 S Dupont Hwy
StateDelaware
CityCamden
Zip19934-1249
CountryUS

About SELLAS Life Sciences Group Inc

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.